Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00428935 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy
A Phase 1 study, sponsored by Nationwide Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00428935 is a Phase 1 study that has completed, run by Nationwide Children's Hospital. The registered enrollment target is 6 participants.
The verdict
NCT00428935, a Phase 1 study, has completed, sponsored by Nationwide Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of a miniature dystrophin gene in the treatment of progressive muscle weakness due to Duchenne Muscular Dystrophy (DMD).
Interventions
- BIOLOGICAL rAAV2.5-CMV-minidystrophin (d3990)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00428935
The ClinicalTrials.gov registry entry for NCT00428935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rAAV2.5-CMV-minidystrophin (d3990) is the first listed.
NCT00428935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00428935 about?
NCT00428935 is a clinical study titled "Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy". The purpose of this study is to determine the safety of a miniature dystrophin gene in the treatment of progressive muscle weakness due to Duchenne Muscular Dystrophy (DMD).
What is the current status of trial NCT00428935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2006-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00428935?
The interventions under investigation include: rAAV2.5-CMV-minidystrophin (d3990) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00428935?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.